Most Common Adverse Reactions

Adverse reactions in patients with type 1 diabetes, excluding hypoglycemia1

The most common adverse events reported in ≥5% of patients treated with SYMLIN® (pramlintide acetate) injection plus insulin and with greater incidence than in patients treated with placebo plus insulin were:

Adverse reactions in patients with type 1 diabetes, excluding hypoglycemia Adverse reactions in patients with type 1 diabetes, excluding hypoglycemia Adverse reactions in patients with type 1 diabetes, excluding hypoglycemia Adverse reactions in patients with type 1 diabetes, excluding hypoglycemia

*Examples of inflicted injury included, among others, abrasions, bruises, burns, fractures, lacerations, and muscle strains.

 

Severe Hypoglycemia

Incidence and event rate of severe hypoglycemia in 6-month, placebo-controlled studies and a dose titration study in patients with type 1 diabetes1

Incidence and event rate of severe hypoglycemia in 6-month, placebo-controlled studies Incidence and event rate of severe hypoglycemia in 6-month, placebo-controlled studies Incidence and event rate of severe hypoglycemia in 6-month, placebo-controlled studies Incidence and event rate of severe hypoglycemia in 6-month, placebo-controlled studies Incidence and event rate of severe hypoglycemia in a dose titration study Incidence and event rate of severe hypoglycemia in a dose titration study Incidence and event rate of severe hypoglycemia in a dose titration study Incidence and event rate of severe hypoglycemia in a dose titration study

aPatient-ascertained severe hypoglycemia:  Requiring the assistance of another individual (including help ingesting oral carbohydrate) and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention.

bMedically assisted severe hypoglycemia:  Requiring glucagon, intravenous glucose, hospitalization, paramedic assistance, emergency room visit, and/or assessed as a serious adverse event by the investigator.